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Background: The altered expression of prolactin (PRL) and its receptor (PRLR) has been implicated in breast and
other types of cancer. There are few studies that have focused on the analysis of PRL/PRLR in cervical cancer where
the development of neoplastic lesions is influenced by the variation of the hormonal status. The aim of this study
was to evaluate the expression of PRL/PRLR and the effect of PRL treatment on cell proliferation and apoptosis in
cervical cancer cell lines.
Results: High expression of multiple PRLR forms and PRLvariants of 60–80 kDa were observed in cervical cancer cell
lines compared with non-tumorigenic keratinocytes evaluated by Western blot, immunofluorecence and real time
PCR. Treatment with PRL (200 ng/ml) increased cell proliferation in HeLa cells determined by the MTT assay at day
3 and after 1 day a protective effect against etoposide induced apoptosis in HeLa, SiHa and C-33A cervical cancer
cell lines analyzed by the TUNEL assay.
Conclusions: Our data suggests that PRL/PRLR signaling could act as an important survival factor for cervical
cancer. The use of an effective PRL antagonist may provide a better therapeutic intervention in cervical cancer.
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Prolactin (PRL) is a pituitary polypeptide hormone with
multiple biological actions which include proliferation and
differentiation of mammary gland cells, beginning and
maintenance of lactation, immunoregulation, osmoregula-
tion, behavior and reproduction [1]. The role of PRL in
tumorigenesis was suggested some decades ago in breast
cancer, mainly in animal-based research [2]. However, the
relevance of extrapolating these results to humans has al-
ways been questioned. Epidemiological studies performed
during the 80s and 90s were unable to reach unified con-
clusions from correlations between circulating PRL levels
and risk for breast cancer [3,4]. Also, clinical studies report
that reducing circulating PRL levels did not improve the
condition of advanced breast cancer patients [5]. This con-
troversial view of PRL in human cancer has been consider-
ably modified in the past 10 years. Now, there is evidence* Correspondence: analauraps@hotmail.com
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distribution, and reproduction in any mediumthat high circulating PRL levels are considered a risk fac-
tor in breast cancer [6,7] and in other reproductive can-
cers such as endometrial, ovarian and prostate [8,9]. In
addition to circulating PRL, there is clear evidence that
several human tissues also express PRL like the mammary
gland, prostate, skin, decidua, brain, some immune cells,
adipocytes, and several others [10]. The biological effects
of PRL are mediated by its interaction with the PRL recep-
tor (PRLR). As PRLR is also expressed in these tissues, co-
expression of both partners suggests the existence of an
autocrine–paracrine loop of action. In recent years, re-
ports supporting the tumor growth potency of local PRL
in humans are emerging [11-14]. Alternative strategies in-
volving PRLR neutralization and PRL antagonists opened
new areas of research in this field.
PRLR belongs to the superfamily of hematopoietic
cytokine receptors. Binding of PRL activates several sig-
naling pathways, which include the Janus kinase-Signal
transducer and activator of transcription (Jak-Stat), the
Mitogen-activated protein kinases (MAPK), and the
phosphoinositide 3 kinase (PI3K). Activation of these
cascades results in endpoints such as differentiation,entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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several prolactin receptor isoforms identified in humans,
including the long form , an intermediate form, two short
forms and soluble receptor isoforms, all of them generated
through mRNA splicing [17-19]. Each of these forms has
the same extra-cellular sequence, but differs in the intra-
cellular signaling. The effects of PRL are dependent on the
expressed PRLR form(s) of PRLR expression; the long and
intermediate forms have been associated with increased
cell proliferation or anti-apoptotic effects while the short
and soluble forms have been described as being dominant
negative [20]. Another mechanism potentially participat-
ing in local amplification of PRLR signaling in tumor con-
texts has recently emerged, and involves gain-of-function
of PRLR variants.
Cervical cancer is a leading cause of morbidity and mor-
tality among women worldwide, especially in developing
countries [21]. Infection with oncogenic types of Human
Papillomavirus (HPV) is an important factor in the devel-
opment of cervical cancer [22]. Despite the evidence that
HPV is strongly implicated as the causative agent of cer-
vical cancer, this infection alone is not sufficient for tumor
development. In addition, the immune system, as well as
microbial, chemical [23,24] and hormonal cofactors play a
role in the development of neoplastic lesions in the uterine
cervix. Indeed, the variation of the hormonal status de-
pending on age, pregnancy or contraceptive use, has been
shown to influence the development of cervical cancers
[25-27]. PRL expression in tissues and serum has been
found elevated in patients with cervical cancer [28,29]
suggesting a possible participation in the development or
progression of the disease. Hence, PRLR expression in cer-
vical cancer has not been well documented and the roles of
PRL and PRLR in tumor development are still unknown. In
the present study, we determined the expression levels of
PRL and PRLR and the effect of PRL treatment on cell pro-
liferation and apoptosis in HeLa, SiHa and C-33A cervical
cancer cell lines. In addition, we antagonized any possible
effect of the locally produced PRL using specific blocking
antibodies against PRL and PRLR.
Methods
Standard culture conditions
Cervical cancer cell lines (HeLa, SiHa, and C-33 A), as well
as two human breast cancer cell lines (MCF-7, T-47D) and
non-tumorigenic human keratinocytes (HaCaT) were
obtained from the American Type Culture Collection
(Rockville, MD); cells were cultured in a water-jacketed in-
cubator at 37°C under an atmosphere of 95% air and 5%
CO2 in RPMI 1640 or DMEM medium supplemented
with 10% fetal bovine serum (FBS), L-glutamine (2 mM),
penicillin (100 U/ml), streptomycin (100 μg/ml). Cell
medium, FBS and antibiotics were obtained from Gibco
(Carlsbad, CA).Western blotting
Cells were seeded into 6-well plates and grown to 80% con-
fluence in growth medium. Proteins were extracted from
cell lines with 300 μl of RIPA buffer (50 mM Tris, 150 mM
NaCl, 1% NP40, 0.5% sodium deoxycholate, and 0.1% so-
dium dodecyl sulfate [SDS]), added with protease inhibi-
tors (pestatin, leupeptin, aprotinin, quimostatin, antipain,
and PMSF) and phosphatase inhibitors (Na3 VO4, and
NAF), and clarified by centrifugation at 4°C for 20 min.
Protein concentration was determined by the Lowry
method (DC Protein Assay, Bio-Rad). Forty micrograms of
total protein were mixed with loading buffer, resolved
on a 7.5-12% SDS- polyacrylamide gels under denatur-
ing conditions and electro-transferred to polyvinylidene
difluoride membranes (Bio-Rad, CA). Nonspecific bind-
ing was blocked with 5% milk and 1% bovine serum
albumin solution. Then, membranes were incubated at
4°C overnight with primary antibodies (diluted 1:1000
for PRLR (H-300 Santa Cruz Biotechnology), 1:500 for
PRL (E-9 Santa Cruz Biotechnology) and 1:10000 for
Actin (MAB1501 Millipore), HRP-conjugated anti-
rabbit or anti-mouse secondary antibody (Santa Cruz
Biotechnology) (diluted 1:5000) was used to reveal the
immune detection and blots were developed with a
chemiluminescence system (Immobilion, Millipore). As an
internal control to confirm that similar amounts of protein
were loaded for each lane, actin levels were determined.
Optical density measurements were determined and
analyzed using Image J analysis software (NIH).
Fluorescent immunocytochemistry
Cells were grown to 80% confluence on 8-well glass cham-
ber slides cover slips (Labtek, Nalgene) in growth medium.
Then, cells were fixed with 4% pararaformaldehide for 10
min at −20°C. Slides were blocked for 90 min with bovine
serum albumin (BSA) at room temperature, permeabilized
with .2% Tween-20 and then incubated overnight at 4°C
with primary antibody diluted 1:50. Next, they were incu-
bated with secondary anti-mouse or anti-rabbit antibodies
coupled to Alexa Fluor 488 (Invitrogen) diluted 1:1000
for 1 h. Cell nuclei were counterstained using 1 μg/ml of
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI)
(Invitrogen). The fluorescent staining pattern was evalu-
ated using an Axio Imager 2 fluorescence microscope
(Carl Zeiss, Göttingen, Germany).
Total RNA isolation and real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions,
spectrophotometric quantification at 260, 280 and 230 nm
was realized using a NanoDrop 1000 Spectrophotometer
(Thermo Fisher Scientific, Inc.). Retrotranscription using
1 μg of total RNA was achieved using M-MLV reverse tran-
scriptase and random primers following the recommended
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performed using an LightCycler Nano Real-Time PCR Sys-
tem (Roche Diagnostics) starting with a 10 min incubation
at 95°C followed by 40 cycles (95°C for 15 sec and 60°C for
1 min). The PCR reaction mixture 20 μl consisted of: 2 μl
of cDNA template (100 ng), 1 μl of 20X TaqMan probes
(Applied Biosystems) PRLR (Hs01061477_m1 FAM la-
beled) or PRL (Hs01062137_m1 FAM labeled) specific, 10
μl of 2X TaqMan Gene Expression Master Mix (Applied
Biosystems) and 7 μl of RNase-free water. PRL and PRLR
mRNA relative expression was calculated using the 2−
ΔΔCq method after validating similar reaction efficiencies
of both the interest gene (PRL and PRLR) and the reference
gene 18s RNA (Hs03928985_g1 VIC labeled, Applied
Biosystems) by running serial dilutions of both genes [30].
Cell proliferation assay (MTTAssay)
Cells (5 × 103) were seeded in 96-well plates and were
allowed to grow for 24 h in growth medium. Growth
medium was replaced with serum free medium supp-
lemented with 10% charcoal striped serum (CSS) before
dosing with PRL 200ng/ml (L7009 Sigma), PRLR neu-
tralizing antibody (MAB1167 R&D systems) or PRL
antibody (6F11 QED Bioscience) for 3 or 5 days. Then
5 μl of 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium reagent (MTT) (5mg/ml) was added to cells
and the cultures and incubated for 3 h at 37°C in a CO2
chamber. Blue formazan crystals were solubilized
with acidified isopropanol, and formazan levels were deter-
mined by measuring absorbance at 570 nm in an Epoch
Microplate Spectrophotometer (Bio-Tek Instruments, Inc.).
Apoptotic assay (TUNEL Assay)
For the TUNEL Assay we used the kit APO-BrdU
(Invitrogen). Cells were grown for 24 h in 8-well chamber
slides seeded with 5 × 104 cells per well were treated and
incubated with etoposide alone and in the presence of
PRL or PRL antibody for 24 hours at 37°C. The slides were
washed in PBS and fixed with 4% paraformaldehyde for 30
min at room temperature. Fixed cells were washed in PBS,
permeabilized with .2% Tween-20 for 10 min on ice, and
then incubated with terminal deoxynucleotidyl transferase
and BrdUTP for 1 h at 37°C. After rinsing with PBS, slides
were treated with Alexa Fluor 488 dye–labeled anti-BrdU
antibody at 37°C for 30 min and mounted with a glass
coverslip. Staining of DNA fragmentation was observed
under ultraviolet fluorescent microscope (Carl Zeiss)
counting at least 200 cells/well.
Statistical analysis
Data was analyzed using Graph pad PRISM software
(Graph pad version 5.01). Significant effects were deter-
mined using ANOVA followed by Student’s t-test, includ-
ing Dunnett´s post-test for multiple comparisons against asingle control group. A statistically significant difference
was considered to be present at p<0.05.
Results
PRLR is highly expressed in cervical cancer cells
PRLR expression was assessed in cervical cancer cell
lines (HeLa, SiHa and C-33A) and human non-
tumorigenic keratinocytes (HaCaT) by western blot,
immunocitochemistry and real time-PCR. Breast can-
cer cell lines T-47D and MCF-7 served as the positive
control. To detect PRLR expression we used an anti-
body raised against amino acids 323–622 of human
PRLR that recognized multiple isoforms. In T-47D and
MCF-7 we observed a high expression of different
bands (110 kDa, 90 kDa, 80 kDa, 60 kDa and 50 kDa)
that corresponded to PRLR isoforms. Differently than
breast cancer cells, in cervical cancer cell lines HeLa,
SiHa and C-33A we detected three of the PRLR forms
(110 kDa, 60 kDa and 50 kDa). However, human non-
tumorigenic keratinocytes (HaCaT) only expressed low
levels of the 50 kDa PRLR band (Figure 1A). The op-
tical density measurements from immunoblots demon-
strated higher PRLR expression in cancer cell lines in
comparison with the non-tumorigenic HaCaT cell line
(Figure 1B).
Next, we observed the localization of PRLR by immuno-
fluorescence. The intensity of fluorescence was augmented
in cancer cell lines compared with HaCaT, which corre-
lates with western blot results. PRLR staining was hetero-
geneous on the cell surface and in the cytoplasm of all
cancer cells lines (Figure 1C). To evaluate relative mRNA
expression levels of PRLR we did real time PCR using a
specific probe that could detect all PRLR isoforms. As can
be seen, the PRLR mRNA detectable in all cervical cancer
cell lines was augmented in comparison with HaCaT that
expressed about 15 to 60 fold decrease (Figure 1D). Cell
lines T47-D and MCF-7 showed the highest PRLR
expression.
Autocrine Prolactin is produced in cervical cancer cells
PRL expression was detected using the same techniques
to evaluate PRLR expression. Our results reveal that
cervical, breast cancer and HaCaT cells express PRL-
like proteins. Interestingly, PRL found in all cell
lines had a higher molecular weight about 60–80 kDa
(Figure 2A). The optical density measurements from
western immunoblots showed augmented PRL expres-
sion in cervical cancer cell lines in comparison with
the non-tumorigenic HaCaT cell line (Figure 2B). A
similar localization of PRL was observed in all cells
studied, the intensity of fluorescence was augmented
in T47-D, MCF-7 and HeLa (Figure 2C). The mRNA





























Figure 1 PRLR expression in human cervical cancer cells. SiHa, C-33A, HeLa (Cervical cancer cells) and control cells MCF-7, T-47D
(breast cancer), HaCaT (Inmortalized human keratinocytes) were cultured in DMEM or RPMI medium containing 10% FBS. A) PRLR protein was
determined by western blot using a specific antibody against the PRLR, PRLR proteins were identified by their size. B) Demonstration of the
arbitrary optical density measurements from Western immunoblots assessing PRLR levels. C) The cells grown on coverslips were fixed, and the
localization of PRLR (green) was observed by inmunocitochemistry using a secondary antibody conjugated with Alexa fluor 488 and DAPI stain
(blue) to visualize the presence of cells. Magnification 10 x. D) Relative expression of PRLR mRNA was measure by quantitative RT-PCR.
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cell proliferation in cervical cancer cells
To test whether PRL had an effect on the proliferation in
cervical cancer cells, we cultured cells in the absence and
presence of PRL, PRLR-AB or PRL-AB for 3 and 5 days.
Treatment with PRL (200 ng/ml) increased the viable
cell number in HeLa about 9% after 3 days of incubation
(Figure 3A); while no effect was observed in SiHa and C-
33A (Figure 3B, C). The incubation with PRLR-AB
(2.5 μg) or PRL-AB (200 ng/ml) had not impact over the
total cell number in cervical cancer cells. Similar dose re-
sponse analyzes with PRL and blocking antibodies were
performed in breast cancer and HaCat cells, observing an
increase of 6% in the cell number of T47-D after 3 days of
incubation with PRL. Moreover, the treatment with PRL
and PRLR antibodies decreased the total cell number in a
range of 5–8% in T47-D and 12-18% in MCF-7 at day 3
(Figure 3D, E). But, this decrease was statistically significant
only in MCF-7 after 3 days of incubation with the PRL-AB.
No effect on cell proliferation in HaCat cells was observed
(Figure 3F). Other dose and time conditions were used in
all the cell lines and no significant difference was detected
in the total cell number (data not shown).Prolactin treatment reduce DNA fragmentation induced
by etoposide
Treatment with etoposide (1 μM) augmented the num-
ber of cells with fragmented DNA in all cell lines after
24 h of incubation, as expected. PRL (200 ng/ml) co-
stimulus significantly decreased the number of cells
with DNA fragmentation from 27.3 to 19.1% in HeLa
cells, from 26.7 to 21.2% in SiHa cells and from 22.1 to
16.4% in C-33A (Figure 4A, B, C). Also, PRL treatment
decreased induced cell death in breast cancer cells, from
28.7 to 18.3% in T47-D cells and from 30.6 to 21% in
MCF-7 cells (Figure 4D, E). PRL had no effect on
cell survival in HaCat cells pretreated with etoposide
(Figure 4F). PRL-AB treatment (200 ng/ml) did not
modify apoptosis induced by etoposide in any of the cell
lines tested. Also, no effect on DNA fragmentation was
found when PRL-AB or PRL was used.
Discussion
To date, several reports associate the expression of the
PRL/PRLR with the development and progression of can-
cers such as breast, prostate, colorectal, gynecological, la-
ryngeal, and hepatocellular [31]. There are few reports
Figure 2 Presence of autocrine PRL in human cervical cancer cell lines. SiHa, C-33A, HeLa (Cervical cancer cells) and control cells MCF-7,
T-47D (breast cancer), HaCaT (Inmortalized human keratinocytes) were cultured in DMEM or RPMI medium containing 10% FBS. A) PRL protein
was determined by western blot using a specific antibody against PRL. B) Demonstration of the arbitrary optical density measurements from
Western immunoblots assessing PRL levels. C) The cells grown on coverslips were fixed, and the localization of PRL (green) was observed by
inmunocitochemistry using a secondary antibody conjugated with Alexa fluor 488 and DAPI stain (blue) to visualize the presence of cells.
Magnification 40 x. D) Relative expression of PRL mRNA was measure by quantitative RT-PCR.
Figure 3 Effects of PRL and PRL or PRLR blocking antibodies on proliferation of cervical cancer cells. Effects on metabolic activity after
the incubation with PRL (200 ng/ml), PRL-AB (200 ng/ml) or PRLR-AB (2.5 μg) for 3 or 5 days in HeLa, SiHa, C-33A (A, B, C) and control cells
MCF-7, T-47D and HaCaT (D, E, F). Graphs show experiments performed in triplicate, which are repeated at least three times. *p<.05.
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Figure 4 Effects of PRL and PRL antibody on apoptosis induced by etoposide. Effects of the treatment with etoposide (40 ug/ml) for 24 hrs
with or without added PRL (200 ng/ml) or PRL-AB (200 ng/ml) in SiHa, C-33 A, HeLa (A, B, C) and control cells MCF-7, T-47D and HaCaT (D, E, F). DNA
strand breaks were analyzed microscopically by TUNEL. Graphs represent the mean of at least three replicate, where *p<0.05, **p<0.01 and ***p<.001.
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pression and its possible role in cervical cancer remains
unknown. A previous study demonstrates that the pres-
ence of PRL was augmented in malignant cervix tissues
[28]. In another work, they reported an increment of
serum PRL levels in a considerable number of patients
with cervical cancer [29]. In a recent study of our investi-
gation group we observed an increased PRLR expression
in cervical cancer samples compared with intraepithelial
cervical lesions (data not published). With this back-
ground information, we decided to evaluate the expression
levels of PRL and PRLR and their possible participation in
cell survival of cervical cancer cell lines.
The results of this study demonstrate that PRLR are
over-expressed at protein and mRNA levels in human cer-
vical cancer cells compared with human non-tumorigenic
keratinocytes. Heterogeneous PRLR staining was observed
on the cell surface and in the cytoplasm. Previous reports
have proposed a mechanism by which PRLR might be-
come stabilized and accumulated in breast cancers. The
proposed mechanism states a constitutive oncogenic sig-
naling downstream of the Ras pathway which inactivates
Glycogen synthase kinase 3 beta and prevents phosphoryl-
ation of PRLR on Ser349 and PRLR ubiquitination, ultim-
ately leading to PRLR stabilization [32,33].Moreover, when we evaluated PRLR expression in
protein extracts from the cervical cancer cell lines, we
observed a high expression of 110 kDa, 60 kDa and 50
kDa bands that could correspond to different PRLR var-
iants previously reported [17-19]. While, in HaCaT cells,
only a 50 kDa band was detected. Actually, several in-
vestigators have focused in revealing the impact of the
expression of specific PRLR isoforms. They have de-
scribed that short PRLR forms act as dominant negative
regulators of the stimulatory actions of the long PRLR
forms in vitro. In prostate cancer, it has also been dem-
onstrated that the long term increased expression of the
PRLR short form 1b in PC-3 human prostate cancer
cells decreases cell growth and migration, and causes
multiple changes in gene expression consistent with re-
duced invasive capacity [34]. Another report showed a
low ratio of short to long PRLR forms in breast cancer
tumors when compared with normal samples; this re-
duced expression in patients with cancer could contrib-
ute to breast tumor development and progression [20].
The expression of multiple PRLR products (that might
correspond to long and short PRLR forms) observed in
cervical cancer cells lines suggests that the specific
evaluation of the PRLR isoforms could be important for
the diagnosis or treatment of the disease.
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in cervical cancer cells through the PRL transcript and
protein. PRL found in the cell lysates had a higher mo-
lecular weight (60–80 kDa) than the PRL peptide of 23
kDa commonly reported. This data is consistent with a
previous report that demonstrated the presence of a
60 kDa PRL-like variant in both normal and systemic
lupus erythematosus (SLE) PBMNC extracts, preferen-
tially expressed in SLE subjects [35]. This PRL variant
could be generated by post-translational modifications
such as glycosylation or phosphorylation [36,37].
PRL and PRLR co-expression observed in cervical can-
cer cells suggests the existence of an autocrine–paracrine
loop of action supporting the cell growth in cervical can-
cer. The results of this study showed that PRL treatment
had significant effects only on HeLa cell proliferation, yet
these effects were not observed in C-33A or SiHa. This
observed difference in response between cervical cancer
cells could be due to the origin of the cells. Since SiHa
and C-33A are derived from a cervical squamous cell car-
cinoma, HeLa cell line is derived from cervical adenocar-
cinoma. Cervical adenocarcinoma arises within glands
located in the endocervix, and it is well documented that
this kind of tumor has an amplified hormonal response.
Although the major association of PRL with human can-
cer is given in breast cancer [6,38]; the role of PRL in the
proliferation of classical breast cancer cell lines is contro-
versial. Some authors have reported that PRL promotes
cell proliferation in some breast cancer cell lines [39]. In
contrast, other investigators showed that PRL had no ef-
fect on cell proliferation in human breast cancer cell lines
MDA-MB-231, T-47D, MCF-7 and Hs578T [40]. The dis-
parity in the results can be influenced by the use of differ-
ent culture techniques and conditions including the use of
different clones of each cell line. One more study, also
reported that PRL treatment had no effect on proliferation
of LNCaP and PC3 prostate cancer cell lines but showed
that PRL has a pro-apoptotic effect in the androgen re-
sponsive cell line LNCaP [41].
Several studies have demonstrated that breast cancer
and others cell lines like ovarian cancer cells produce
autocrine PRL, and that the incubation with PRL anti-
bodies and other PRLR antagonists reduce the cell num-
ber [42-44]. In our experiments, we did not find an effect
over the proliferation of the cervical cancer cells using
PRL or PRLR antibodies, yet a decrease in the number of
cells after treatment can be appreciated in the MCF-7 and
T47-D cell lines previously reported.
However, we did find that treatment with PRL had a
protective effect against cell death induced by etoposide,
decreasing the number of apoptotic cells in all the cervical
cancer cell lines. Similar results were obtained in T-47D
and MCF-7, but not in HaCaT cells. This suggests that
PRL has an important role in the cell survival of cervicaland breast cancer. A similar result has been reported in
breast cancer cell lines T-47D, MCF-7 and Hs578T, show-
ing that PRL has the ability to prevent breast cancer cells
from undergoing apoptosis after the treatment with C2-
ceramide [40].
At signaling level, it has been reported that even if Jak2
is essential for the proliferative effects of PRL in the onset
of induced mammary tumorigenesis, the deletion of Jak2
following neoplastic transformation had no significant im-
pact on the survival and growth of mammary cancer cells
in culture and in vivo [45]. We cannot exclude that PRLR
signaling is still capable of promoting breast cancer pro-
gression and invasion through Jak2/Stat5-independent
pathways such as c-Src, FAK, and MAP kinases and be-
yond towards proliferative effects; thus, other PLR roles
are currently being diligently investigated. PRL could favor
cell motility and confer resistance to chemotherapy, and
thereby contribute to metastasis dissemination [6,46]; such
diverse effects may be mediated by distinct PRLR signaling
cascades.
Conclusions
In summary, we demonstrated that human cervical cancer
cell lines HeLa, SiHa and C33A over-expressed multiple
PRLR forms, and also produced autocrine PRL-like pro-
teins. In addition, PRL augmented cell proliferation in
HeLa cells and had a protective effect against etoposide in-
duced apoptosis in HeLa, SiHa and C-33A, suggesting that
PRL/PRLR signaling could act as an important survival
factor for cervical cancer. Our data supports the hypoth-
esis that the use of an effective PRL antagonist may pro-
vide a better therapeutic intervention in cervical cancer.
More studies are necessary to determine the signaling
pathways activated by PRL and could support the trans-
formation mechanisms activated in those cell lines and
hence in cervical cancer.
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